XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 10, 2021
Oct. 10, 2020
Jun. 23, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 20, 2018
Dec. 31, 2020
Accounts payable and accrued expenses       $ 11,712,477       $ 11,712,477     $ 11,973,981
Accrued interest       936,134       936,134     742,374
Net income (loss)       (1,936,543) $ (2,379,056) $ (2,173,903) $ 757,866 (6,489,502) $ 1,651,867    
Revenue       13,595,418     14,352,098 40,061,419 39,105,318    
Grigorios Siokas Four [Member]                      
Borrowing       1,529,500       1,529,500      
Grigorios Siokas [Member]                      
Borrowing                   $ 1,718,400  
Litigation settlement $ 600,000                    
Plantiff attorney fees 120,000                    
Litigation cost $ 4,137                    
Accounts payable and accrued expenses       124,137       124,137      
Forgiveness to additional paid in capital       600,000       600,000      
Outstanding principal balance       463,080       463,080     489,200
Accrued interest       240,586       240,586     193,585
Interest rate                   4.70%  
Maturity date                   Mar. 18, 2019  
Grigorios Siokas Three [Member]                      
Borrowing       1,562,895       1,562,895      
Outstanding principal balance       3,000,000       3,000,000     1,629,246
Convertible share description     Mr. Siokas whereby an aggregate total of $3,000,000 of these outstanding loans were converted into 500,000 shares of the Company’s common stock                
Net income (loss)               $ 4,846      
Additional proceeds from debt       1,281,562              
Repayment of loans       (1,000,000)              
Foreign curreny translation       (20,577)              
Stock converted               166,667      
Conversion               $ 1,250,000      
Description of debt instrument               the Company borrowed additional proceeds of €1,350,000 ($1,562,895), €230,000 ($275,306) and $3,993,380 and repaid €106,000 ($122,716) of these loans. Included in the $3,993,380 is a convertible promissory note issued to Mr. Siokas on July 20, 2021 for $2,000,000 in exchange for $2,000,000 in cash proceeds      
Dimitrios Goulielmos [Member]                      
Outstanding principal balance       11,809       $ 11,809     12,475
Foreign curreny translation       (19,977)              
Loss incured       26,786       26,786      
DOC Pharma S.A. [Member]                      
Payments to purchase products       761,552     2,441,256 2,164,913 3,994,896    
Accounts payable balance       81,457       81,457      
Accounts receivable balance       2,924,075       2,924,075     3,468,564
Prepaid balance       2,253,351       2,253,351     $ 3,468,653
Net prepaid balance       2,171,893       2,171,893      
Revenue       $ 44,950     $ 208,625 $ 835,914 $ 1,696,904    
Description of research and development               Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the nine months ended September 30, 2021, SkyPharm bought 67 licenses at value of €261,300 ($302,507) from Doc Pharma which was the 18.33% of the total cost. The agreement will be terminated on December 31, 2025.      
DOC Pharma S.A. [Member] | Outsourcing Agreement [Member]                      
Pieces per product   1,000                  
Inventroy purchase   $ 1,835,603                  
Agreement term   5 years